Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
Azusa TanimotoShingo MatsumotoShinji TakeuchiSachiko AraiKoji FukudaAkihiro NishiyamaKiyotaka YohTakaya IkedaNaoki FuruyaKazumi NishinoYuichiro OheKoichi GotoSeiji YanoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These clinical and preclinical results indicate concomitant TP53 mutations reduce the efficacy of alectinib for ALK-rearranged NSCLC and the combined use of a proteasome inhibitor with alectinib is a promising therapy for ALK-rearranged/TP53-mutated NSCLC.